Treatment aimed for high-risk patients, including immunosuppressed (cancer, HIV, AIDS, transplant) patients, pregnant patients, adults ≥65 years old, and patients with asthma, chronic heart disease, or diabetes
Treatment options can lessen symptoms (including pneumonia) by 1-2 days and decrease length of stay when started within 2 days of symptoms
Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season. MMWR Recomm Rep 2021;70(5):1-28.
Ison MG, Fraiz J, Heller B, et al. Intravenous peramivir for treatment of influenza in hospitalized patients. Antivir Ther. 2014;19(4):349-61. DOI: 10.3851/IMP2680.
Eyler RF, Heung M, Pleva M, et al. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Pharmacotherapy. 2012 Dec;32(12):1061-9.
Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58:309–318.